Latest & greatest articles for ketamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ketamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ketamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ketamine

1. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Full Text available with Trip Pro

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Consensus Guidelines on the Use of Intravenous Ketamine Infu... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account Registered (...) Articles & Issues Collections For Authors Journal Info > > Consensus Guidelines on the Use of Intravenous Ketamine Infu... Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). Message: Thought you might appreciate this item(s) I saw at Regional Anesthesia and Pain Medicine. Send a copy to your email Your message has been successfully sent to your colleague. Some error has occurred while processing your request

2018 American Society of Regional Anesthesia and Pain Medicine

2. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management Full Text available with Trip Pro

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management Consensus Guidelines on the Use of Intravenous Ketamine Infu... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) navigation Articles & Issues Collections For Authors Journal Info > > Consensus Guidelines on the Use of Intravenous Ketamine Infu... Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). Message: Thought you might appreciate this item(s) I saw at Regional Anesthesia and Pain Medicine. Send a copy to your email Your message has been successfully sent to your colleague. Some error has occurred while processing your

2018 American Society of Regional Anesthesia and Pain Medicine

3. Ketamine for chronic pain

Ketamine for chronic pain Ketamine for chronic pain We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Ketamine for chronic pain Share: Reading time approx. 12 minutes Patients with complex and chronic pain conditions may experience that conventional pain management with for example opioids is insufficient for pain relief. Ketamine is mainly used (...) in anaesthesia, but in lower doses may also be used for pain management in the acute setting. Question What clinical evidence exists for the treatment of low-dose intravenous ketamine for chronic pain conditions? Table with identified studies Table 1. Overviews over systematic reviews Included studies Population Outcome Bell and Kalso 2018 [1] 18 systematic reviews Several populations: chronic noncancer pain, refractory cancer pain, opioid-resistant pain in palliative care, postoperative pain (chronic

2019 Swedish Council on Technology Assessement

4. Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder

Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Health Problem: Treatment-resistant depression (TRD) is typically defined as depression that does not respond to at least 2 attempts at treatment of adequate duration with appropriate doses of antidepressants, but there is no official consensus definition. Posttraumatic stress disorder (PTSD) is an anxiety

2017 Health Technology Assessment (HTA) Database.

5. Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Full Text available with Trip Pro

Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Ketamine for treatment-resistant depression: recent developments and clinical applications | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ketamine for treatment-resistant depression: recent developments and clinical applications Article Text Clinical review Ketamine for treatment-resistant depression: recent developments

2016 Evidence-Based Mental Health

6. Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial Full Text available with Trip Pro

Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial Timely analgesia is critical for children with injuries presenting to the emergency department, yet pain control efforts are often inadequate. Intranasal administration of pain medications provides rapid analgesia with minimal discomfort. Opioids are historically used for significant pain from traumatic injuries but have concerning adverse effects. Intranasal (...) ketamine may provide an effective alternative.To determine whether intranasal ketamine is noninferior to intranasal fentanyl for pain reduction in children presenting with acute extremity injuries.The Pain Reduction With Intranasal Medications for Extremity Injuries (PRIME) trial was a double-blind, randomized, active-control, noninferiority trial in a pediatric, tertiary, level 1 trauma center. Participants were children aged 8 to 17 years presenting to the emergency department with moderate to severe

2019 EvidenceUpdates

7. Ketamine infusion for treatment-resistant bipolar depression

Ketamine infusion for treatment-resistant bipolar depression Ketamine infusion for treatment-resistant bipolar depression Ketamine infusion for treatment-resistant bipolar depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine infusion for treatment-resistant bipolar depression. Lansdale: HAYES, Inc. Healthcare Technology (...) Brief Publication. 2017 Authors' conclusions Health Problem: Bipolar disorder is a chronic illness characterized by alternating periods of profound depression and excessively elevated or irritable mood (mania). These episodes of extreme mood are interspersed by periods of relatively normal mood. Bipolar disorder is a severely impairing illness associated with unemployment, decreased productivity, and excess mortality. Technology Description: Ketamine therapy for bipolar disorder often involves

2017 Health Technology Assessment (HTA) Database.

8. Ketamine Analgesia for Acute Pain in the Emergency Department

Ketamine Analgesia for Acute Pain in the Emergency Department Emergency Medicine > Journal Club > Archive > April 2016 Toggle navigation April 2016 Ketamine Analgesia for Acute Pain in the Emergency Department Vignette It's two o'clock in the afternoon during a typical weekend TCC shift, when you get a page that a triage patient is coming to room 4. You look at the chart and see that it's a 45-year-old man who was riding his horse and got bucked off, landing on his left arm in an awkward (...) your attending about the IV lidocaine, which the patient says hasn't really helped his pain, but Dr. Cohn just shakes his head and sighs. You then ask about giving the patient low-dose ketamine for his pain, having recently listened to a podcast on the subject ( ). Dr. Cohn laughs in your face and turns his back on you. Later, he comes back and explains that while he admittedly hasn't read the literature on the subject, he isn't a big fan of replacing one addictive substance with another

2017 Washington University Emergency Medicine Journal Club

9. Is Low-Dose Ketamine an Effective Alternative to Opioids for Acute Pain? Full Text available with Trip Pro

Is Low-Dose Ketamine an Effective Alternative to Opioids for Acute Pain? Is Low-Dose Ketamine an Effective Alternative to Opioids for Acute Pain? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 73, Issue 5, Pages e47–e49 Is Low-Dose Ketamine an Effective Alternative to Opioids for Acute Pain? x Jonathan M. Kirschner , MD (EBEM Commentator) , x Benton R. Hunter , MD (EBEM Commentator) Department (...) of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN DOI: | Publication History Published online: December 11, 2018 Expand all Collapse all Article Outline Take-Home Message In adult emergency department (ED) patients with acute pain, low-dose intravenous ketamine (0.3 to 0.5 mg/kg) may provide pain relief within 10 minutes that is similar to that of single-dose intravenous morphine (0.1 mg/kg). Methods Data Sources A medical librarian searched MEDLINE, EMBASE, Scopus, Cochrane

2019 Annals of Emergency Medicine Systematic Review Snapshots

10. Ketamine

Ketamine Top results for ketamine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ketamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

11. Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression

Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine as an adjunct (...) Description: Intravenous injection (IV) of ketamine hydrochloride as an adjunct to electroconvulsive therapy (ECT) is intended to reduce symptoms of depression more rapidly and to a greater extent than ECT alone in patients who have TRD. Controversy: Early evidence for the antidepressant effect of ketamine came from uncontrolled studies and TRD may have diverse causes and poor response rates that make it difficult to demonstrate whether or not ketamine treatment is effective. Key Questions: Does ketamine

2017 Health Technology Assessment (HTA) Database.

12. Ketamine for depression: where do we go from here? Full Text available with Trip Pro

Ketamine for depression: where do we go from here? Ketamine for depression: where do we go from here? Ketamine for depression: where do we go from here? aan het Rot M, Zarate CA, Charney DS, Mathew SJ CRD summary The review concluded that ketamine seemed a reasonable treatment option for most patients with treatment resistant depression when administered by trained clinicians in appropriate settings. This was a poorly reported review that was at risk of various forms of bias. The synthesis (...) was limited which suggests that definitive conclusions cannot be drawn, and the authors’ conclusions cannot be considered reliable. Authors' objectives To evaluate the antidepressant effects of ketamine for patients with major depressive episodes. Searching PubMed was searched to January 2012 for relevant articles; search terms were reported. ClinicalTrials.gov was also searched for studies that were unpublished, currently recruiting participants or not yet enrolling. Additional relevant studies cited

2012 DARE.

13. Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Full Text available with Trip Pro

Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Ketamine showed no cognitive or other benefit when given alongside ECT, but the study recruited fewer participants than planned and moderate benefits or harms cannot be excluded. {{author}} {{($index , , , , , , , , , , , , , , , , , , , & . Ian M Anderson 1, * , Andrew

2017 NIHR HTA programme

14. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Full Text available with Trip Pro

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression (...) and with better tolerability. However, no study so far has directly compared esketamine with racemic ketamine. Here we propose a protocol of a clinical trial to evaluate esketamine as a noninferior medication when compared to ketamine in the treatment of patients with treatment-resistant depression.This study protocol is for a randomized, controlled, double-blind noninferiority clinical trial. Subjects will be 18 years or older, with major depression characterized as treatment-resistant. Participants

2018 Medicine Controlled trial quality: predicted high

15. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial Full Text available with Trip Pro

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major (...) depressive disorder.In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1).The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d

2018 EvidenceUpdates

16. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Management Full Text available with Trip Pro

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Management Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists | Regional Anesthesia & Pain Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists Article Text Chronic and Interventional Pain: Special Article Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American

2018 American Academy of Pain Medicine

17. IM Ketamine for Prehospital Sedation of the Agitated Patient

IM Ketamine for Prehospital Sedation of the Agitated Patient Emergency Medicine > Journal Club > Archive > November 2016 Toggle navigation November 2016 IM Ketamine for Prehospital Sedation of the Agitated Patient Vignette You are working a night shift in EM-1 and have just started to catch up after signout, consisting of more than a few inebriated patients awaiting sobriety, when you hear commotion out in the hall. EMS and police are bringing in a large, screaming, Blailing, adult male patient (...) that might reduce the chances for injury of the patient and providers? How about something that is more rapid in onset than our old “5 and 2”? You remember hearing that ketamine is now being stocked on some ambulances for this purpose. When you wake up the next day after your shift you decide to look into the evidence behind prehospital ketamine for agitated patients. PICO Question Population: Adult patients with severe agitation requiring chemical sedation in the prehospital setting Intervention: IM

2017 Washington University Emergency Medicine Journal Club

18. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial (Abstract)

Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the antidepressant effects of a single ketamine infusion, a series of repeated ketamine infusions, and prolongation of response (...) with maintenance infusions.Forty-one participants with treatment-resistant depression completed a single-site randomized double-blind crossover comparison of single infusions of ketamine and midazolam (an active placebo control). After relapse of depressive symptoms, participants received a course of six open-label ketamine infusions administered thrice weekly over 2 weeks. Responders, classified as those participants who had a ≥50% decrease in their scores on the Montgomery-Åsberg Depression Rating Scale

2019 EvidenceUpdates

19. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. (Abstract)

ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side (...) effects. Ketamine has emerged as the first rapid-acting antidepressant and shows robust short-term efficacy in clinical trials, but there are concerns about its long-term safety and efficacy. While response rates are similar between ECT and ketamine in clinical trials, these treatments have never been compared head-to-head in a sufficiently large, well-powered randomized study. Here we describe the study protocol for ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant

2019 Contemporary clinical trials Controlled trial quality: uncertain

20. Chronic pain: oral ketamine

Chronic pain: oral ketamine Chronic pain: or Chronic pain: oral k al ketamine etamine Evidence summary Published: 25 February 2014 nice.org.uk/guidance/esuom27 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in February 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Two small, short-term (...) , randomised, placebo-controlled trials and 1 small case series of n-of-1 trials provide no good quality evidence for the use of oral ketamine to treat chronic pain in adults. Only 1 phase I pilot study in young people was identified but this was too small and short-term to draw any firm conclusions about the efficacy and safety of oral ketamine for treating chronic pain in young people. In the studies that reported safety, oral ketamine was frequently associated with adverse effects that often resulted

2014 National Institute for Health and Clinical Excellence - Advice